Cellular Changes in Prostate Cancer Cells Induced by Intermittent Androgen Suppression

European Urology

Volumn 52, Issue 3, 2007, Pages 725-732

  Laitinen, Sari ^a   Martikainen, Paula M ^b   Tammela, Teuvo L J ^b   Visakorpi, Tapio ^a  

^a UNIVERSITY OF TAMPERE   (Finland)

^b TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

Author keywords

Androgen receptor; Castration; Neoplasia; Prostatic carcinoma

Indexed keywords

ANDROGEN RECEPTOR; CASPASE 3; CYPROTERONE ACETATE; GOSERELIN; KI 67 ANTIGEN;

APOPTOSIS; ARTICLE; CANCER CELL; CASTRATION; CELL PROLIFERATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; GLEASON SCORE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; NEEDLE BIOPSY; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; TUMOR GROWTH;

ANDROGEN ANTAGONISTS; ANDROGENS; ANTINEOPLASTIC AGENTS, HORMONAL; APOPTOSIS; BIOPSY, NEEDLE; CASPASE 3; CELL PROLIFERATION; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; FOLLOW-UP STUDIES; GOSERELIN; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; MALE; NEOPLASM STAGING; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TESTOSTERONE; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 34547169546     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2006.11.043     Document Type: Article

References (40)

1. Huggins C., and Hodges C.V. Studies on prostatic cancer I. The effects of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1 (1941) 293-297
2. Tammela T. Endocrine treatment of prostate cancer. J Steroid Biochem Mol Biol 92 (2004) 287-295
3. Palmberg C., Koivisto P., Visakorpi T., and Tammela T.L. PSA decline is an independent prognostic marker in hormonally treated prostate cancer. Eur Urol 36 (1999) 191-196
4. Gittes R.F. Carcinoma of the prostate. N Engl J Med 324 (1991) 236-245
5. Crawford E.D., Eisenberger M.A., McLeod D.G., et al. A controlled trial of leprolide with and without flutamide in prostatic carcinoma. N Engl J Med 321 (1989) 419-424
6. Denis L.J., Carnelro de Moura J.L., Bono A., et al. Goserelin acetate and flutamide versus bilateral orchidectomy. A phase III EORTC trial (30853). Urology 42 (1993) 119-129
7. Petrylak D.P., Tangen C.M., Hussain M.H.A., et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351 (2004) 1513-1520
8. Aus G., Abbou C.C., Bolla M., et al. EAU guidelines on prostate cancer. Eur Urol 48 (2005) 546-551
9. Samson D.J., Seidenfeld J., Schmitt B., et al. Systematic review and meta-analysis of monotherapy compared with combined androgen blockade for patients with advanced prostate carcinoma. Cancer 95 (2002) 361-376
10. Kyprianou N., Martikainen P., Davis L., English H.F., and Isaacs J.T. Programmed cell death as a new target for prostatic cancer therapy. Cancer Surv 11 (1991) 265-277
11. Akakura K., Bruchovsky N., Goldenberg S.L., et al. Effects of intermittent androgen suppression on androgen-dependent tumors: apoptosis and serum prostate specific antigen. Cancer 71 (1993) 2782-2790
12. Goldenberg S.L., Bruchovsky N., Gleave M.E., et al. Intermittent androgen suppression in the treatment of prostate cancer: a preliminary report. Urology 45 (1995) 839-844
13. Grossfeld G.D., Small E.J., and Carroll P.R. Intermittent androgen deprivation for clinically localized prostate cancer, initial experience. Urology 51 (1998) 137-144
14. Horwich A., Huddart R.A., Gadd J., et al. A pilot study of intermittent androgen deprivation in advanced prostate cancer. Br J Urol 81 (1998) 96-99
15. Daniell H.W. Osteoporosis due to androgen deprivation therapy in men with prostate cancer. Urology 58 suppl 1 (2001) 101-107
16. Gleason D.F. Histological grading and clinical staging of carcinoma. In: Tannenbaum M. (Ed). Urologic pathology. The prostate (1977), Lea & Feibiger, Philadelphia
17. Westin P., Stattin P., Damber J.E., and Bergh A. Castration therapy rapidly induces apoptosis in minority and decreases cell proliferation in majority of human prostatic tumors. Am J Pathol 46 (1995) 1368-1375
18. Ohlson N., Wikström P., Stattin P., and Bergh A. Cell proliferation and apoptosis in prostate tumors and adjacent non-malignant prostate tissue in patients at different time-points after castration treatment. Prostate 62 (2005) 307-315
19. Paterson R.F., Gleave M.E., Jones E.C., Zubovits J.T., Goldenberg S.L., and Sullivan L.D. Immunohistochemical analysis of radical prostatectomy specimens after 8 months of neoadjuvant hormonal therapy. Mol Urol 3 (1999) 277-286
20. Miayata Y., Kanda S., Sakai H., Hakariya T., and Kanetake H. Relationship between changes in prostate cancer cell proliferation, apoptotic index, and expression of apoptosis-related proteins by neoadjuvant hormonal therapy and duration of such treatment. Urology 65 (2005) 1238-1243
21. Matsushima H., Goto T., Hosaka Y., Kitamura T., and Kawabe K. Correlation between proliferation, apoptosis, and angiogenesis in prostate carcinoma and their relation to androgen ablation. Cancer 85 (1999) 1822-1827
22. Buhler K.R., Santuci R.A., Royai R.A., et al. Intermittent androgen suppression in the LuCaP 23.12 prostate cancer xenograft model. Prostate 43 (2000) 63-70
23. Bladou F., Vessella R.L., Buhler K.R., Ellis W.J., True L.D., and Lange P.H. Cell proliferation and apoptosis during prostatic tumor xenograft involution and regrowth after castration. Int J Cancer 17 (1996) 785-790
24. Landstrom M., Damber J.E., and Bergh A. Prostatic tumor regrowth after initially successful castration therapy may be related to a decreased apoptotic cell death rate. Cancer Res 54 (1994) 4281-4284
25. Wikström P., Westin P., Stattin P., Damber J.E., and Bergh A. Early castration induced upregulation of transforming growth factor β1 and its receptors is associated with tumor cell apoptosis and a major decline in serum prostate specific antigen in prostate cancer patients. Prostate 38 (1999) 268-277
26. Häggström S., Stattin P., Wikström P., Bergh A., and Damber J.E. Castration induced reduction of vascular endothelial growth factor expression in non-malignant human prostate tissue is lost in advanced prostate cancer. BJU Int 88 (2001) 110-116
27. Reuter V.E. Pathological changes in benign and malignant prostatic tissue following androgen deprivation therapy. Urology 49 suppl (1997) 16-22
28. Yri O.E., Bjoro T., and Fossa S.D. Failure to achieve castration levels in patients using leuprolide acetate in locally advanced prostate cancer. Eur Urol 49 (2006) 54-58
29. Bostwick D.G., Qian J., Civantos F., Roehrborn C.G., and Montironi R. Does finasteride alter the pathology of the prostate and cancer grading?. Clin Prostate Cancer 2 (2004) 228-235
30. Bostwick D.G. Grading prostate cancer. Am J Clin Pathol 102 suppl (1994) S38-S56
31. Vaillaincourt L., Têtu B., Fradet Y., et al. Effect of neoadjuvant endocrine therapy (combined androgen blockade) on normal prostate and prostatic carcinoma: a randomized study. Am J Surg Pathol 20 (1996) 86-93
32. Rubin M.A., Allory Y., Molinié V., et al. Effects of long-term finasteride treatment on prostate cancer morphology and clinical outcome. Urology 66 (2005) 930-934
33. Clarke N.W. Management of the spectrum of hormone refractory prostate cancer. Eur Urol 50 (2006) 428-439
34. Linja M.J., and Visakorpi T. Alterations of androgen receptor in prostate cancer. J Steroid Biochem Mol Biol 92 (2004) 255-264
35. Stanbrough M., Bubley G.J., Ross K., et al. Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. Cancer Res 66 (2006) 2815-2825
36. Tan J., Sharief Y., Hamil K.G., et al. Dehydroepiandrosterone activates mutant androgen receptors expressed in the androgen-dependent human prostate cancer xenograft CWR22 and LNCaP cells. Mol Endocrinol 11 (1997) 450-459
37. Metzger E., Muller J.M., Ferrari S., Buettner R., and Schule R. A novel inducible transactivation domain in the androgen receptor: implications for PRK in prostate cancer. EMBO J 22 (2003) 270-280
38. Paule B. Reappraisal of the concept of hormone therapy in metastatic prostate cancer and implications for treatment. Eur Urol 47 (2005) 729-735
39. Baretton G.B., Klenk U., Diebold J., Schmeller N., and Lohrs U. Proliferation- and apoptosis-associated factors in advanced prostatic carcinomas before and after androgen deprivation therapy: prognostic significance of p21/WAF1/CIP1 expression. Br J Cancer 80 (1999) 546-555
40. Furuya Y., Kawauchi Y., and Fuse H. Cell proliferation, apoptosis and prognosis in patients with metastatic prostate cancer. Anticancer Res 23 (2003) 577-581